Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

Government

Macro Economic Events

News

Politics

Legal

Economics

General

STLA

TSLA

Watching Shares Of Domestic Automakers; Reuters Reports Letter Sent By Major Automakers Urging Congress To Block California's Plan To End Sales Of Gas-Only Vehicles By 2035

Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares got a slight bump in early trading Monday. The company announced the termination of a 2018 consent order from the <a href="https://www.benzinga.com/pressreleases/25/04/b45036401/wells-fargo-confirms-termination-of-2018-cfpb-compliance-consent-order">Consumer Financial Protection Bureau (CFPB)</a>.
What Happened: Wells Fargo on Monday confirmed that the CFPB&#8217;s consent order related to the company&#8217;s risk management program has been terminated, representing the twelfth consent order closed by Wells Fargo regulators since 2019. 
&#8220;Today&#8217;s termination, along with the recent closure of other consent orders, demonstrates that we have completed much of our common risk and control infrastructure work, including work that is required by other orders,&#8221; said Charlie Scharf, CEO of Wells Fargo.
&#8220;I am proud of the work done by our teams and remain confident that we will complete the work needed to close our other open consent orders. Wells Fargo is a different and stronger company today as we focus on creating long-term value for our customers, clients, communities and shareholders.&#8221;
See Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45035728/5-stocks-in-the-spotlight-last-week-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight Last Week: Wall Street&#8217;s Most Accurate Analysts Weigh In</a>
<h3 class="wp-block-heading">How To Buy WFC Stock</h3>
By now you're likely curious about how to participate in the market for Wells Fargo &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Wells Fargo, which is trading at $69.73 as of publishing time, $100 would buy you 1.43 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
WFC Price Action: <a href="http://benzinga.com/quote/WFC">Wells Fargo shares</a> were up 0.32% at $69.95 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Bumble Dee/Shutterstock.

Movers

What's Going On With Wells Fargo Stock Today?

Barclays analyst Andrew Mok maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $93 to $84.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Centene, Lowers Price Target to $84

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near our pivot point at 549.67. Bulls are aiming to initiate a climb towards the next upside level at 550.45. Sustained bullish momentum above this area would then open the path to our next reference at 551.33. Holding steadily above 551.33 through regular trading could encourage further upside to 552.50, with the ultimate bullish objective today set at 553.66.
Conversely, if 549.67 fails to maintain support, sellers are expected to target 549.00 initially. Increased bearish activity could then lead to a deeper probe down to 548.13. Should selling accelerate aggressively past 548.13, we expect a firm test of support at 547.56. In a highly bearish scenario, the lower boundary for SPY today is projected at 546.46.
Invesco QQQ Trust Series 1 (QQQ)
The QQQ is trading around our critical point of 471.33. Bulls must actively defend this mark and demonstrate enough strength to push upward, first to 474.66. Solidifying above 474.66 would enhance bullish conviction and potentially drive prices up to 476.85. Robust buyer activity throughout the session could extend this advance towards 479.03, with our top bullish expectation today at 481.73.
On the downside, if the market struggles around 471.33, sellers are likely to seize the opportunity, initially targeting 469.27. Further weakness could encourage bears to explore lower support around 467.60. Persistent selling pressure might bring into focus the next key downside level at 465.93. If this area is breached convincingly, the bearish scenario targets 463.56.
Apple Inc. (AAPL)
Apple is trading near our significant level at 209.81. Bulls aim to secure this level early and then propel the price upward toward the next resistance at 211.12. Continued bullish activity could push Apple shares even higher to the level at 212.44. Sustained buying strength could then lead Apple to test the upper bullish target for today at 214.07.
Should support at 209.81 fail to hold during the trading session, sellers would likely test the lower boundary at 208.81. A continued bearish move could pressure the price further down to 207.93. Sustained selling could extend downward pressure towards 207.18, with a breakdown possibly leading Apple to our lowest bearish target of 206.55.
Microsoft Corp. (MSFT)
Microsoft shares are hovering close to our central pivot at 390.98. Bulls seek a definitive move above 392.49 to solidify buying momentum and challenge the next upside target at 393.47. A successful retest of 393.47 as reliable support could encourage bullish traders to pursue higher levels, starting with 394.46. Continued strong buying would ultimately target today&#8217;s bullish high at 395.68.
If support at 390.98 weakens significantly, bearish traders are expected to first test downside levels near 389.29. Breaking below this initial support would set up another downward move toward 388.53. Continued bearish momentum may push the price lower to 387.60. If bearish sentiment dominates, Microsoft&#8217;s lowest bearish target today is projected at 386.09.
NVIDIA Corporation (NVDA)
NVIDIA&#8217;s price is currently near our essential pivot point at 109.12. Bulls are targeting an upward push toward 109.86 and ideally converting this level into reliable intraday support. Strong buyer conviction could then drive the price higher to the next resistance at 110.73. With sustained bullish activity, the price could climb towards 111.70, ultimately aiming for today&#8217;s upper bullish target at 112.54.
On the downside, if support at 109.12 fails decisively, bearish traders will initially focus on lower levels near 107.51. Should sellers persist aggressively, the price could quickly drop to 106.30. A continued bearish scenario would further test downside strength at 105.23, with the lowest bearish objective today positioned at 103.96.
Alphabet Inc Class A (GOOGL)
Alphabet shares are trading close to our identified pivot at 161.79. Bulls must maintain stability here to build positive momentum and target the next level upward at 163.79. Continued bullish action could allow buyers to reach our top bullish objective today at 165.41.
Should 161.79 weaken during the trading session, bears would aim to drive the price down initially toward 160.36. Additional bearish pressure could prompt sellers to test lower supports at 158.54. In the event of heavy selling momentum, Alphabet shares may move sharply lower to today&#8217;s ultimate bearish level at 157.41.
Meta Platforms Inc (META)
Meta shares are trading around our pivot at 553.05. Bulls must maintain control above this price to target higher levels, beginning with a move toward 559.29. Continued strong buying could then push the market upward to 565.53. If bullish momentum remains persistent, we anticipate a rally toward our high bullish objective today at 573.25.
If support at 553.05 collapses during the session, bearish traders are expected to target an immediate decline toward 548.44. Continued selling pressure might accelerate downward to 541.79. Should the bearish scenario intensify further, Meta shares could approach today&#8217;s lowest bearish target at 537.68.
Tesla Inc. (TSLA)
Tesla shares are currently trading near our key pivot at 288.80. Bulls will seek immediate upside momentum, first targeting resistance at 290.47. Continued bullish activity could further propel the price upward toward our important reference at 293.21. A sustained bullish market move could then extend toward 294.60, with today&#8217;s upper bullish limit positioned at 296.44.
Conversely, if 288.80 breaks down, we anticipate bears targeting lower supports at 286.34. Persistent selling could lead to additional downward pressure toward 283.95. In the case of increased bearish sentiment, Tesla&#8217;s lowest bearish target today is at 281.32.
Final Word:&nbsp;
Today's economic calendar is notably sparse, with just two significant data releases. At 10:30 AM ET, market participants will receive the Dallas Fed Manufacturing Activity index for April, providing insight into regional economic trends. Additionally, at 11:30 AM ET, the Treasury will conduct its auction of 3-month and 6-month bills, potentially influencing short-term rates.
Given the minimal economic data, market attention will largely shift toward strategic positioning ahead of more impactful releases later this week, notably the JOLTS and NFP reports. Traders should also remain vigilant for news developments, especially concerning trade tariffs and ongoing international trade tensions, which could inject volatility into today&#8217;s market session. Stay focused, manage risks carefully, and have a profitable trading day!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Trading Ideas

Technical Analysis For Trading SPY And Top Tech Stocks

Susquehanna analyst Joseph Stauff initiates coverage on Madison Square Garden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) with a Positive rating and announces Price Target of $254.

Initiation

MSGS

Susquehanna Initiates Coverage On Madison Square Garden with Positive Rating, Announces Price Target of $254

Barclays analyst George Wang maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight and lowers the price target from $157 to $126.

Barclays Maintains Overweight on Celestica, Lowers Price Target to $126

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading lower Monday. Reports from the weekend indicated that China&#8217;s Huawei Technologies has developed an AI chip to <a href="https://www.benzinga.com/markets/equities/25/04/45033025/nvidia-faces-new-challenge-as-huawei-tests-powerful-ascend-910d-ai-chip-amid-us-sanctions-aiming-to-disrupt-high-end-market-report">directly challenge Nvidia</a>. 
What To Know: Huawei has developed a new AI processor called Ascend 910D that it hopes will be a replacement for some higher-end chips made by Nvidia, the Wall Street Journal <a href="https://www.wsj.com/tech/chinas-huawei-develops-new-ai-chip-seeking-to-match-nvidia-8166f606">reported</a> on Sunday. 
People familiar with the matter said Huawei already approached some Chinese technology companies with intentions of testing the technical practicability of the new chip. 
Development of the chip is still in the early stages, but the company could reportedly receive its first sample batches by late May. This latest version of the company&#8217;s Ascend AI processor is expected to be more powerful than Nvidia's H100.
The news comes after Nvidia said in a regulatory filing earlier this month that the U.S. government informed the company that it will <a href="https://www.benzinga.com/news/global/25/04/44828742/nvidia-stock-is-tumbling-after-hours-heres-why">need a license</a> to export&nbsp;certain chips to China, focused on the company&#8217;s H20 chips.
A license will also be required for any other circuits achieving the H20&#8217;s memory bandwidth, interconnect bandwidth, or a combination thereof, Nvidia said in the filing.
Check This Out: <a href="https://in.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Chamath Palihapitiya Says Nvidia Is Huawei&#8217;s &#8216;New Target&#8217; — A &#8216;National Champion&#8217; That Crushed Tech Giants With A &#8216;Low-End Disruptor&#8217; Strategy</a>
As a result of the restrictions, Nvidia said it expects its first-quarter financial results to include up to $5.5 billion of charges associated with H20 products held in inventory. Nvidia&#8217;s fiscal first quarter ended on Sunday and the company is due to report financial results for the period next month.
Analysts currently expect the chipmaker to report earnings of 88 cents per share and revenue of $43.09 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Huawei&#8217;s new chip is the latest version of its Ascend processor, with previous versions being called 910B and 910C. The report indicates that the Chinese chipmaker is expected to ship more than 800,000 Ascend 910B and 910C chips to customers this year. Some buyers are also reportedly in talks to increase orders following the chip restrictions from the Trump administration. 
NVDA Price Action: <a href="http://benzinga.com/quote/nvda">Nvidia shares</a> were down 0.96% at $109.94 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/45014765/if-you-invested-10k-in-nvidia-stock-10-years-ago-how-much-would-you-have-now">If You Invested $10K In Nvidia Stock 10 Years Ago, How Much Would You Have Now?</a></li>
</ul>
Photo: Hepha1st0s/Shutterstock.

Global

NVDA

Nvidia Stock Is Sliding Monday Morning: What's Going On?

Susquehanna analyst Joseph Stauff initiates coverage on Liberty Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Positive rating and announces Price Target of $115.

FWONK

Susquehanna Initiates Coverage On Liberty Media with Positive Rating, Announces Price Target of $115

Global active health and wellness company prioritizes scalable, future-proof solutions to support growth and complexity

ETWO

Nutrabolt Partners With e2open For Digital Supply Chain Transformation

Susquehanna analyst Joseph Stauff initiates coverage on Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Positive rating and announces Price Target of $155.

Susquehanna Initiates Coverage On Live Nation Entertainment with Positive Rating, Announces Price Target of $155

Revvity Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) stock is trading higher on Monday after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45034099/revvity-announces-financial-results-for-the-first-quarter-of-2025" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
The Waltham, Massachusetts-based company reported first-quarter sales of $664.76 million, down from $709.07 million, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $661.18 million</a>.
&#8220;Our first quarter performance positions us well for the remainder of the year as we continue to adapt to an evolving macroeconomic backdrop,&#8221; Revvity CEO Prahlad Singh said.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42490115/despite-higher-valuations-some-life-sciences-tools-stocks-create-good-opportunities-analyst" rel="noreferrer noopener">Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst</a>
Here&#8217;s a breakdown of the financials:
<ul>
<li>First-quarter adjusted EPS of $1.01, beating the consensus of 95 cents.</li>
<li>Adjusted operating income was $170 million compared to $166 million for the same period a year ago. </li>
<li>Adjusted operating profit margin was 25.6% compared to 25.5% in the same period a year ago.</li>
<li>The company&#8217;s life sciences segment <a href="https://s202.q4cdn.com/560601150/files/doc_financials/2025/q1/1Q25-Quarterly-Investor-Presentation-vFinal.pdf" target="_blank" rel="noreferrer noopener">saw</a> revenue tick up 1% to $340 million. In addition, organic revenue increased by 2%, diagnostics sales increased 3% year-over-year to $324 million, and organic diagnostics revenue increased 5%.</li>
</ul>
Guidance: Revvity affirms the fiscal year 2025 adjusted EPS of $4.90-$5.00 versus consensus of $4.94.
The company raised its 2025 sales guidance from $2.8 billion to $2.85 billion, compared to the consensus of $2.83 billion.
The guidance reflects the impact of foreign currency exchange at -0.5% rates and assumes 3%-5% organic revenue growth.
The company forecasts a 2025 adjusted operating margin of 27.9%-28.1%.
Price Action: Revvity stock is up 5% at $99 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/45014623/avantor-sees-steady-earnings-plans-leadership-change-and-strategy-shift" target="_blank" rel="noreferrer noopener">Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Health Care

RVTY

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

WIIM

NVIDIA shares are trading lower following reports indicating China's Huawei Technologies has developed an AI chip to challenge the company.

Mizuho analyst Gabriel Moreen maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Outperform and lowers the price target from $226 to $218.

TRGP

Mizuho Maintains Outperform on Targa Resources, Lowers Price Target to $218

AAPL

'Apple's iPhone 17 Has Completed Its Engineering Verification Phase, But The Supply Chain Conservatively Forecasts A Double-Digit Year-On-Year Shipment Decline In 2025 Due To The Trump Administration's Aggressive And Fluctuating Tariff Policies. These Tariffs Also Impact iPad, Macbook, And Wearable Device Shipments, With Production Shifting Partially From China To India And Vietnam Amid Ongoing Economic Uncertainties.' - DigiTimes Alert

Wedbush analyst Richard Anderson maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and lowers the price target from $24 to $22.

Wedbush Maintains Outperform on Healthpeak Properties, Lowers Price Target to $22

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">94.80</td>
<td align="right">0.44</td>
<td align="right">0.46</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.14</td>
<td align="right">0.12</td>
<td align="right">0.24</td>
<td>141.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.87</td>
<td align="right">0.03</td>
<td align="right">0.03</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">208.13</td>
<td align="right">-0.34</td>
<td align="right">-0.17</td>
<td>16.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">137.86</td>
<td align="right">-0.19</td>
<td align="right">-0.14</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">82.30</td>
<td align="right">-0.09</td>
<td align="right">-0.11</td>
<td>9.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

Leading And Lagging Sectors For April 28, 2025

Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) shares are trading higher premarket on Monday. The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 billion.
Net sales <a target="_blank" href="https://www.cemex.com/w/cemex-reports-record-first-quarter-net-income-new-ceo-with-strong-commitment-to-bolster-shareholder-return" rel="noreferrer noopener">fell </a>7% year over year (Y/Y), mainly due to lower volumes in Mexico.
Mexico sales declined 25% Y/Y to $981 million, United States sales fell 4% Y/Y to $1.19 billion, Europe, Middle East, and Africa rose 2% Y/Y to $1.07 billion, and South, Central America, and the Caribbean increased 2% Y/Y to $314 million.
EBITDA declined 18% Y/Y to $601 million in the quarter, with a margin contracted 2.0ppt Y/Y to 16.5% in the quarter.
Lower volumes and weather-related maintenance activity impacted the EBITDA margin.
Segment-wise, operating EBITDA fell 27% Y/Y in Mexico, 20% Y/Y in the United States and 3% Y/Y in South and Central America and the Caribbean, while it increased 40% Y/Y in Europe, the Middle East and Africa segment.
Outlook: Cemex expects recurrent yearly EBITDA savings of at least $150 million in<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> 2025 and $350 million by 2027</a>.
Given the macroeconomic uncertainties and anticipated savings from Project Cutting Edge, the company continues to forecast flat EBITDA performance <a href="https://www.cemex.com/documents/d/cemex/1q25-presentation-english" target="_blank" rel="noreferrer noopener">for </a>2025.
Cemex remained optimistic about volume growth in EMEA and SCAC, anticipates improved performance in Mexico, and expects stable market conditions in the U.S. during the second half of 2025.
The company projects FCF to deliver $500 million in savings in 2025.
Price Action: CX shares are up 2.53% at $6.070&nbsp;premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45029247/unitedhealth-t-mobile-and-fiserv-are-among-top-12-large-cap-losers-last-week-apr-21-apr-25-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">UnitedHealth, T-Mobile And Fiserv Are Among Top 12 Large-Cap Losers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?</a></li>
</ul>

Mid Cap

Cemex's Q1 Results Show Strong EMEA Growth, Offset by Mexican Market Struggles

Wedbush analyst Jay McCanless upgrades Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) from Neutral to Outperform and raises the price target from $38 to $43.

Upgrades

Wedbush Upgrades Tri Pointe Homes to Outperform, Raises Price Target to $43

Mizuho analyst Ben Chaiken maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Outperform and lowers the price target from $62 to $59.

DKNG

Mizuho Maintains Outperform on DraftKings, Lowers Price Target to $59

Barclays analyst Luke Sergott maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Overweight and lowers the price target from $18 to $15.

AVTR

Barclays Maintains Overweight on Avantor, Lowers Price Target to $15

Press Releases

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Comments

Kezar Life Sciences

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL